Oppenheimer has upgraded Alcon Inc (NYSE:ALC) following firm first-quarter earnings and several new drivers coming into view.
The analyst sees a new opportunity in glaucoma with the announced acquisition of BELKIN Vision for $60 million immediately and up to $335 million with milestone payments.
Via the BELKIN Vision deal, Alcon adds FDA-approved Eagle direct-SLT for glaucoma. Selective Laser Trabeculoplasty (SLT) stimulates the trabecular meshwork to increase fluid drainage/lower Intraocular pressure (IOP).
The analyst also writes that Eagle has differentiating characteristics including shorter treatment time. Once closed, BELKIN will broaden ALC’s reach into glaucoma treatment.
The analyst also highlights:
- The …
Full story available on Benzinga.com